“It’s a black box,” he said.īut the crackdown on Didi, given the size of the company, was “sending the signal that any tech company or data-rich company, as soon as they’re going to reach a certain critical mass, will be under very harsh scrutiny” if they seek an overseas listing. Nicolas Bahmanyar, a data privacy consultant at Leaf Law Firm, said it was still unclear which private companies might be defined by the regulator as operating “critical information infrastructure” for the purpose of such reviews. Those measures, which came into force on June 1 last year and are backed by China’s National Security Law and its Cybersecurity Law, empower it to probe firms deemed to operate “critical information infrastructure.” But it marks the first time the nation’s year-old cybersecurity review measures have been publicly enacted. which it ordered to stop registering new users.ĬAC has made no specific allegations about the firms, all of which listed on U.S. On Monday the probe widened to online recruitment platform Boss Zhipin, run by Kanzhun Ltd., and Yunmanman and Huochebang - two truck-booking apps run by Full Truck Alliance Co. plunged this week after the Cyberspace Administration of China (CAC) first announced a probe of the firm’s national security and cybersecurity risks, and then ordered the ride-hailing giant’s app to be removed from local app stores, all within days of its $4.4 billion U.S. The planned rule changes would allow regulators to block a Chinese company from listing overseas even if the unit selling shares is incorporated outside China, closing a loophole long-used by the country’s technology giants.Ĭhinese technology stocks were routed after the announcement, continuing a trend that has seen some $823 billion wiped from their market value since a February peak, amid a raft of regulatory hits spanning financial risk, privacy, antitrust, and now national security. China will toughen laws and regulations on the management of confidential information and hold publicly traded companies accountable for keeping their data secure, it said. The document pledged to step up oversight of cross-border data flows, a long-running policy trend which is likely to create additional hurdles for private Chinese firms operating and listing overseas. The delay comes after the general offices of China’s ruling Communist Party and State Council published a document Tuesday announcing tightened scrutiny of domestic companies’ overseas share sales and data security. LinkDoc was slated to price its offering on Thursday, aiming to raise as much as $211 million. listing since a Chinese regulator announced national security and cybersecurity probes of three freshly listed Chinese technology firms this month, including ride-hailing giant Didi. LinkDoc is the first company known to have pulled out of a U.S. IPO as the fallout from China’s crackdown on data-rich companies listing overseas continues.Ī spokesperson for Tiger Brokers, one of the underwriters of the Linkdoc deal, confirmed the listing had been suspended, telling Caixin that Tiger customers who had signed up to buy the shares had been notified. For more information on this topic, please see Oncology Clinical Data Anlaysis Systems Developer LinkDoc Completes Series B, MD 4/05/16 issue.Alibaba-backed medical data firm LinkDoc Technology Ltd. LinkDoc has also partnered with Tianjin Chest Hospital to develop the first lung cancer AI-based medical diagnosis support platform in the Tianjin-Beijing-Hebei area.Įditor's Note: LinkDoc was set up in December 2014, and mainly focuses on developing information systems for oncology specialists, helping clinics, for example, to establish EMR systems which allow doctors to check information relating to their patients' diagnoses and treatment. As its data and technology resources have grown, the company has launched new AI-based diagnosis and treatment services and innovative pharmaceuticals industry services since early 2018. Zhang Tianze, CEO at LinkDoc, said that as of H1 2018 its medical big data platform covers approximately 60% of oncological disease types. Participating in the round was sovereign wealth fund China Investment Corporation. Oncology Clinical Data Analysis Firm LinkDoc Wins RMB 1 Bln Series D iHeima, 7/04/18īeijing-based oncology-focused clinical data analysis systems developer LinkDoc Technology recently announced completion of RMB 1 bln in Series D funding in H1 2018.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |